Immunic, Inc. is a late-stage biotechnology company developing oral small-molecule therapies for neurologic and gastrointestinal diseases. The company's lead program, vidofludimus calcium (IMU-838), is in Phase 3 clinical trials for relapsing multiple sclerosis and has shown activity in progressive multiple sclerosis. The pipeline includes IMU-856, a Sirtuin 6 modulator for gastrointestinal conditions such as celiac disease and inflammatory bowel disease, and IMU-381, a next-generation molecule leveraging the Nurr1 platform for neurologic and autoimmune diseases. Immunic operates through its subsidiary Immunic AG, which conducts research and development in Germany, and Gliomic Therapeutics Inc., which focuses on brain cancer treatments. The company was founded in 2016 and has operated under its current name since 2019.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage imux.com
Sector Healthcare IR page ir.imux.com
Tags
multiple sclerosis, oral small molecules, neurology, gastroenterology, autoimmune diseases, celiac disease, inflammatory bowel disease, nurr1 platform, dhodh inhibition, clinical-stage, vidofludimus calcium, IMU-838, IMU-856, IMU-381, Immunic AG, Gliomic Therapeutics Inc.
Press page imux.com/news

Metrics

Valuation  
Market cap $ 111.956M
Market cap (USD) $ 111.956M
P/E -3.20
PEG —
P/BV 1.07
P/S —
P/OCF -1.17
P/FCF -1.16
Dividend yield —
Turnover / mcap —
Returns  
ROE 1,456.2%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score -27.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Assets 24.052M 40.868M 54.299M 127.753M 139.1M 167.861M 65.955M 14.978M 60.384M 64.026M 89.081M 108.082M 46.585M
Net profit -97.172M -100.507M -93.612M -120.407M -92.945M -44.017M -34.933M -41.475M -52.078M -40.969M -52.023M -47.667M -32.718M
Free cash flow -85.967M -85.03M -71.162M -65.256M -83.3M -46.27M -28.6M -43.762M -41.082M -36.33M -52.292M -42.234M -30.132M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 0.83 1.15 1.75 1.26 9.75 15.2 6.96 — — — — — —
Price performance 12m -0.28 -0.34 0.39 -0.87 -0.36 1.18 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 150,000 63,000 520,000 679,000 992,000 1.56M 1.33M 1M 577,000
Cash and deposits (USD) 60M 56.9M 13.3M 29.4M 127M 86.9M 107M 46.7M 35.7M 15.5M
Right-of-use assets (USD) — — — 633,000 901,000 948,000 1.55M 1.3M 991,000 575,000
Cash flow detail
Operating cash flow (USD) -35.8M -40.4M -43.2M -28.5M -46.1M -83.2M -65.1M -70.8M -84.8M -85.8M
Purchases of property, plant and equipment (USD) -556,000 -685,000 -597,000 -55,000 -146,000 -67,000 -112,000 -334,000 -264,000 -161,000
Purchases of intangible assets (USD) — — — -75,000 0.00 — — — — —
Change in payables (cash effect) (USD) -459,000 287,000 -770,000 -462,000 1M 176,000 799,000 817,000 3.15M 1.24M
Share-based compensation (USD) 4.68M 5.48M 3.74M 6.51M 2.75M 5.95M 7.93M 7.1M 8.53M 8.86M
Free cash flow (OCF - PPE - intangibles) (USD) -36.3M -41.1M -43.8M -28.6M -46.3M -83.3M -65.3M -71.2M -85M -86M
Income detail
Research and development expense (USD) 30M 39.3M 24.8M 22.5M 38.6M 61.1M 71.3M 83.2M 80M 82M
↳ 5y CAGR +50.5% +2.6% -10.6% -0.6% +15.3% +12.6% +27.4% +28.9% +16.2%
Total comprehensive income (USD) -41M -52.1M -41.5M -35.5M -46.8M -89.1M -117M -92.9M -100M -98.7M
Comprehensive income to owners (USD) -41M -52.1M -41.5M -35.5M -46.8M -89.1M -117M -92.9M -100M -98.7M
Reported Mar 7, 2017 Mar 4, 2019 Mar 4, 2019 Feb 26, 2021 Feb 26, 2021 Feb 24, 2022 Feb 23, 2023 Feb 22, 2024 Mar 31, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 –

– Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled Expected in the First Half of 2027 –

– Executive Leadership Team Further Strengthened with Appointments of Chief Data and Digital Officer and Chief People Officer to Support Regulatory and Commercial Readiness –

NEW YORK, November 13, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history,” said Erik Lundgren, Chief Executive Officer of Immunic.

Immunic, Inc. — Regulation FD Disclosure Bull 0 Bear 0 Routine

On November 5, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “PMS R&D Day”). The PMS R&D Day will take place on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference. The Company intends to use a presentation during the PMS R&D Day (the “Presentation”) which is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K, and the Presentation, regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements.

NEW YORK, October 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.

In addition to members of Immunic’s management team, including Erik Lundgren, M.B.A., Chief Executive Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer, Hella Kohlhof, Ph.D., Chief Scientific Officer, and Jason Tardio, M.B.A., President & Chief Operating Officer, the event will feature presentations by two renowned experts in the treatment of MS and development of new therapies, Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy.

The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Immunic management will highlight the potential expansion opportunity for lead investigational asset vidofludimus calcium (IMU-838) in progressive MS, including the clinical and scientific rationale supporting Immunic’s plans to initiate a Phase 3 progressive MS trial later in 2026. The differentiated profile of vidofludimus calcium, including its activity as a nuclear receptor-related 1 (Nurr1) activator and the potential neuroprotective effects associated with this mechanism, provides scientific rationale for its evaluation in progressive forms of MS.

The Virtual Progressive MS R&D Day will take place on Thursday, November 5, 2026, at 12:30 pm ET. To register for the event, please CLICK HERE .

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com .

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Prompts

Immunic, Inc. (ticker IMUX), listed in United States.

Company History

Date Change Detail
Feb 13, 2019 Renamed VITAL THERAPIES INC → IMMUNIC, INC.

ETFs Holding Immunic, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.33% 30,725 $ 225.214K Nov 17, 2026
AVSC 0.00% 17,523 $ 126.691K Nov 16, 2026